Skip to main content
. 2020 Apr 24;99(6):1161–1176. doi: 10.1007/s00277-020-04028-z

Table 3.

Current clinical trials involving ruxolitinib combinations

Drug 1 Drug 2 Phase NCT number
Ruxolitinib Decitabine I/II NCT02076191
PRM-151 II NCT01981850
GS-6624 II NCT01369498
LDE225 I/II NCT01787552
PU-H71 NCT03935555
Navitoclax II NCT03222609
Umbralisib I NCT02493530
Parsaclisib II NCT02718300
PIM447 Ib NCT02370706
Itacitinib II NCT03144687
Pevonedistat I NCT03386214
Luspatercept II NCT03194542
Peg-interferonalpha-2a I/II NCT02742324
Sotatercept
vismodegib Ib NCT02593760